uniQure (QURE) Income from Continuing Operations (2016 - 2026)
uniQure (QURE) recorded quarterly Income from Continuing Operations of 53535000.0 in Q1 2026, down 187.14% quarter-over-quarter from 18644000.0 in Q4 2025, and down 22.68% on a YoY basis from 69240546.4 in Q1 2025.
uniQure (QURE) Income from Continuing Operations (2016 - 2026) Analysis & Trends
uniQure's Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 53535000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 22.68% year-over-year to 53535000.0; the TTM figure through Mar 2026 stood at 189322000.0 (up 3.95% YoY), while the FY2025 annual figure was 178550000.0, up 17.98% from the prior year.
- Income from Continuing Operations was 53535000.0 for Q1 2026 at uniQure, down from 18644000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6807000.0 in Q4 2022 to a low of 89571000.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 52195235.29 across 5 years, with a median of 52798000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations sank 1175.45% in 2023, then soared 64.69% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 6807000.0 in 2022, then tumbled by 1175.45% to 73206000.0 in 2023, then climbed by 27.88% to 52798000.0 in 2024, then jumped by 64.69% to 18644000.0 in 2025, then plunged by 187.14% to 53535000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 53535000.0 (Q1 2026), 18644000.0 (Q4 2025), and 79424000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn | -53.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.54 Mn |
| Dec 31, 2025 | -18.64 Mn |
| Sep 30, 2025 | -79.42 Mn |
| Jun 30, 2025 | -37.72 Mn |
| Mar 31, 2025 | -43.64 Mn |
| Dec 31, 2024 | -52.80 Mn |
| Sep 30, 2024 | -44.38 Mn |
| Jun 30, 2024 | -56.30 Mn |
| Mar 31, 2024 | -65.62 Mn |
| Dec 31, 2023 | -73.21 Mn |
| Sep 30, 2023 | -89.57 Mn |
| Jun 30, 2023 | -68.47 Mn |
| Mar 31, 2023 | -77.23 Mn |
| Dec 31, 2022 | 6.81 Mn |
| Sep 30, 2022 | -47.86 Mn |
| Jun 30, 2022 | -39.06 Mn |
| Mar 31, 2022 | -46.68 Mn |
| Dec 31, 2021 | 11.42 Mn |
| Sep 30, 2021 | -36.53 Mn |
| Jun 30, 2021 | 399.47 Mn |